Asciminib + Nilotinib
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Conditions
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Trial Timeline
Nov 21, 2022 → Jul 7, 2031
NCT ID
NCT05456191About Asciminib + Nilotinib
Asciminib + Nilotinib is a phase 3 stage product being developed by Novartis for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT05456191. Target conditions include Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05456191 | Phase 3 | Active |
Competing Products
20 competing products in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Imatinib Mesylate | Novartis | Phase 2 | 52 |
| Nilotinib | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 3 | 77 |
| STI571 400 mg + STI571 600 mg | Novartis | Phase 2 | 52 |
| Induction Phase + Re-Induction Phase + Post-Remission + Maintenance | Novartis | Phase 2 | 52 |
| nilotinib | Novartis | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Blinatumomab + Asciminib | Novartis | Phase 1/2 | 41 |
| Asciminib | Novartis | Phase 1 | 33 |
| Asciminib Pediatric formulation group + Asciminib Adult formulation group | Novartis | Phase 1/2 | 41 |
| Nilotinib + LDE225 | Novartis | Phase 1 | 33 |
| Nilotinib | Novartis | Approved | 85 |
| Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib | Novartis | Phase 3 | 77 |
| Asciminib | Novartis | Approved | 85 |
| Blinatumomab | Amgen | Phase 2 | 51 |
| Treatment with blinatumomab given subcutaneously. | Amgen | Phase 2 | 51 |
| Blinatumomab + Blinatumomab + HyperCVAD | Amgen | Phase 3 | 76 |
| Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen | Amgen | Phase 3 | 76 |
| Bosutinib | Pfizer | Phase 1/2 | 40 |
| Bosutinib + Bosutinib | Pfizer | Phase 1 | 32 |